Breast Cancer
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
- Details
ClinicalTrials.gov ID:
NCT05514054
Diagnosis Type:
NA
USOR Number:
- Address
4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302